Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Japanese aged 40 to 75 years old~* Moderate to severe chronic obstructive pulmonary disease (COPD) with smoking history of at least 20 pack years~Exclusion Criteria:~* History of hospitalization for COPD exacerbation within past 6 months~* Use of long-term oxygen therapy~* History of asthma~* Respiratory tract infection within past 1 month~* Consistently very high or low blood sugar~* Clinically abnormal laboratory values or significant condition~* History of heart failure or heart attack within past 6 months~* History of long QT syndrome or long QT interval in electrocardiogram recorded at screening~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg (Type: EXPERIMENTAL): In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg (Type: EXPERIMENTAL): In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg (Type: EXPERIMENTAL): In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo (Type: EXPERIMENTAL): In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).